Dr. Dominique Costantini, M.D. Co-founded OSE Pharma SA in 2012 and serves as its Chief Executive Officer. In May 2016, Dr. Costantini led the merger between OSE Pharma and Effimune to jointly found OSE Immunotherapeutics SA, a biotech company specialized in the activation and regulation of the immune response in immuno-oncology, in autoimmune conditions and in transplantation and is its Chief Executive Officer and Director. Dr. Costantini serves as the President of Carthera. She is a Senior Executive and Chief Executive Officer and has more than 20 years experience in pharma /biotech industry including key positions at HMR (now Sanofi) in management of research, pharmaceutical and clinical development and medico -marketing activities (Immunology, Infectiology, Vaccines, Asthma, Oncology, AINS ) MD, Immunology Necker Paris. She served as Development Director of OSE Immunotherapeutics SA. Dr. Costantini founded BioAlliance Pharma in 1997 and served as its Chief Executive Officer until June 2011. She has been a Director of TheraDiag SA since April 27, 2017. She has been an Independent Director of Sensorion SA since May 30, 2017. She has been a Director of OSE Pharma SA since April 27, 2012 and ABIVAX S.A. since September 15, 2015. She is a Member of the Board of Directors at O4CP and Theranexus. She served as an Independent Director of AB Science S.A. since November 12, 2013. She secured more than 150m and significant royalties from industrial partnerships with companies in Europe, the United States and Asia. Her main achievements include various fund raisings with major VC’s firms, IPO and PIPE, more than 100M€ raised as well as international development up to registration of Setofilm, Sitavir, Livatag for HCC in phase 3 and key industrial partnering worldwide. Dr. Costantini serves as a Medical Doctor with a degree in immunology from Necker Paris V.

Immunology, Immunotherapeutics